Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim
Public ClinicalTrials.gov record NCT04638829. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Prospective, Multi-center, Open-label Study Measuring Safety and Treatment Satisfaction in Adult Subjects With Chronic Immune Thrombocytopenia (ITP) After Switching to Avatrombopag From Eltrombopag or Romiplostim
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Evaluate the safety and tolerability of avatrombopag given for 90 days after stopping treatment with eltrombopag or romiplostim.
Study identification
- NCT ID
- NCT04638829
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 60 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 15, 2021 (Actual)
- Primary completion
- Jan 3, 2024 (Actual)
- Completion
- Jan 3, 2024 (Actual)
- Last update posted
- Jan 16, 2025
2021 – 2024
United States locations
- U.S. sites
- 20
- U.S. states
- 14
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sobi Site 110 | Tucson | Arizona | 85745 | — |
| Sobi Site 119 | Whittier | California | 90603 | — |
| Sobi Site 123 | Washington D.C. | District of Columbia | 20010 | — |
| Sobi Site 129 | Miami | Florida | 33143 | — |
| Sobi Site 120 | Ocala | Florida | 34474 | — |
| Sobi Site 125 | St. Petersburg | Florida | 33709 | — |
| Sobi Site 118 | Tampa | Florida | 33606 | — |
| Sobi Site 126 | Chicago | Illinois | 60612 | — |
| Sobi Site 109 | Peoria | Illinois | 61614 | — |
| Sobi Site 124 | New Orleans | Louisiana | 70112 | — |
| Sobi Site 101 | Bethesda | Maryland | 20817 | — |
| Sobi Site 103 | Lincoln | Nebraska | 68506 | — |
| Sobi Site 121 | Chapel Hill | North Carolina | 27514 | — |
| Sobi Site 116 | Greenville | North Carolina | 27834 | — |
| Sobi Site 128 | Cleveland | Ohio | 44106 | — |
| Sobi Site 127 | Philadelphia | Pennsylvania | 19104 | — |
| Sobi Site 102 | York | Pennsylvania | 17403 | — |
| Sobi Site 104 | Rock Hill | South Carolina | 29732 | — |
| Sobi Site 113 | Dallas | Texas | 75246 | — |
| Sobi Site 108 | Salt Lake City | Utah | 84132 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04638829, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 16, 2025 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04638829 live on ClinicalTrials.gov.